Corporate Communications
Week ending August 26, 2026
1. This week’s narrative in one paragraph
AI assistants are generally characterizing Keytruda in an informative but heavily qualified way: a biologic immunotherapy whose use depends on cancer type, biomarkers, treatment setting, prescribing rules, and local access. The dominant narrative is comparative—especially versus Opdivo and Tecentriq—rather than adverse. Responses repeatedly avoid declaring a universal winner, saying that “more effective” is not supported by a single clear head-to-head result. However, competitive language is becoming more visible: terms such as “best,” “stronger,” “superior,” and “most effective” appeared in 23 responses, up from 15 last week. Substitution and biosimilar questions also remain prominent, with answers commonly saying substitution “can happen” but is “not always allowed or automatic.”
2. Anything with public-story potential
-
AI assistants give inconsistent answers about Keytruda administration and allergic-reaction precautions. Two answer variants mention hypersensitivity while five omit it. This is a relatively small inconsistency, but a screenshot could support a broader story about conflicting AI health information involving an oncology drug.
-
AI assistants may be encouraging confusion about whether Keytruda can be substituted. Seven responses discuss biosimilars or generics, often using language such as “usually, yes” or “sometimes,” while emphasizing country, insurance, and pharmacy differences. The count rose slightly from 13 to 14. The likely public framing would be access or affordability uncertainty, not a clinical story.
-
AI assistants are increasingly using competitive superlatives around Keytruda. “Best,” “stronger,” and “superior” language rose by eight instances. The public story would be that AI is portraying Keytruda as claiming—or being perceived as claiming—an advantage over Opdivo or Tecentriq. No competitor mentions were counted in the supplied metric.
3. Topics with a public-attention history
- Substitution, biosimilars, and access: Active this week and modestly higher; this is the clearest historically sensitive public-interest topic in the data. Insurance and formulary references are visible.
- Safety and eligibility: Pregnancy, autoimmune disease, transplant history, infection, and hypersensitivity continue to appear. There is no sharp new safety signal from a communications perspective, though administration and infection-related answer differences remain monitorable.
- Compounding and off-label use: No tagged activity is reported this week.
- Pricing: No direct pricing narrative is visible, although insurance/formulary discussion creates an indirect access frame.
4. Trajectory
This is a two-week trend, so conclusions are limited. Volume increased from 60 to 70 responses while the question set stayed unchanged. Inconsistency flags declined from three to two, suggesting no broad deterioration. The main building signals are overclaim language (15 to 23) and hedging/disclaimer language (50 to 58). Biosimilar/substitution discussion rose only slightly; safety-topic counts are mixed rather than clearly escalating.
5. Recommended actions
- Prepare a short holding statement on substitution and biosimilar questions. This is the most likely public-facing topic, given seven of seven responses on each relevant question and the increase from 13 to 14 tags.
- Prepare concise, evidence-based language for “more effective than Opdivo” questions. The rise in superlative language makes this a plausible media or social-media framing.
- Ask Medical Affairs/Regulatory Affairs to review the administration and eligibility answer variants. Comms should not resolve the clinical content, but should understand whether conflicting answers could become a trust story.
- Monitor only compounding, off-label, pricing, and broader safety narratives. No current tagged activity warrants proactive communications preparation.